【Destiny Pharma-Product XF-73】Destiny Pharma Awarded Grant to Fund Collaboration with Cardiff University Targeting Fungal Infections

Partner News

9th June, 2020 –
Destiny Pharma
issued an announcement,
which is summarized as follows: 

Collaboration will
test antimicrobial candidates from the Company’s XF drug platform against oral
fungal infections.

Destiny Pharma today announces it has been jointly awarded a
National Biofilms Innovation Centre (NBIC) grant to fund a research
collaboration with Cardiff University. The project will establish the potential
of three of the Company’s proprietary XF drug compounds, DPD-207, XF-70 and
XF-73 as novel treatments for clinically important fungal infections in mucosal
mouth models of disease. Financial terms of the collaboration have not been

Oral fungal biofilms are responsible for a significant number
of serious oral infections, but successful treatment is hindered by biofilm
resistance and a limited number of effective antifungal drugs. This project
will evaluate the XF drug candidates in combatting Candida biofilms and their
infection risk using Cardiff’s specialised oral mucosal models.

Oral candidosis occurs in an estimated 2 million people
worldwide. Candida infection of the oesophagus affects an estimated ~1.3
million people and the global oral candidosis market is expected to reach US$
9.5 billion by 2023.

Original website Link: